Page 98 - Priority Review News Today

The FDA has accepted for Priority Review the NDA for tofersen for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.

Total revenues increased 4% in H1 2022 to US$96.8 million, supported by increases in physicians prescribing and number of patients Strong balance sheet and stable cash flow from RUCONEST providing

Lillys revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the...

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) has lowered its 2022 reported EPS guidance by $0.34 to now be in the range of $6.96 to $7.11 and lowered non-GAAP EPS guidance by $0.25 to now

Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue followin

The big hit has been for its insulin Lispro products. Since January 1, Lispro and Humalog have dropped 26% to $447.1 million in the first quarter.

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across...

The US FDA has granted priority review to Gamida Cell’s BLA for omidubicel to treat blood cancer patients who need hematopoietic stem cell transplant.

The FDA has accepted the BLA for omidubicel for the treatment of patients with blood cancers in need of allogeneic hematopoietic stem cell.

The FDA has accepted for Priority Review the sNDA for ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis.